GSK Poised for Pfizer Battle in RSV Vaccine Market
3 minute readPublished: Thursday, October 13, 2022 at 10:37 am
The British pharmaceutical giant said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial, paving the way for a contest with Pfizer Inc. in what the companies expect to be a lucrative market.